文献速递消化、代谢与肾脏急症

成人2型糖尿病的自动胰岛素输注:一项非随机临床试验

Automated Insulin Delivery in Adults With Type 2 Diabetes: A Nonrandomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2025-02-03
一句话结论在成人2型糖尿病胰岛素治疗者中,使用Omnipod 5自动胰岛素输注系统13周后HbA1c降低0.8个百分点,低血糖非劣于标准治疗,作者认为可能是有益且安全的选择。

这项单臂前瞻性试验在美国21个临床中心纳入305例18-75岁、使用胰岛素至少3个月的2型糖尿病成人,先进行14天标准治疗,随后使用Omnipod 5自动胰岛素输注系统13周。主要终点HbA1c从基线8.2%降至13周7.4%,平均差-0.8(95%CI -1.0至-0.7)个百分点,非劣效和优效P均<.001。目标血糖范围(70-180 mg/dL)时间从45%增至66%,平均差20(95%CI 18至22)个百分点,P<.001;低血糖时间非劣于标准治疗。发生1例严重低血糖,无糖尿病酮症酸中毒或高渗性高血糖综合征。作者认为自动胰岛素输注可能是使用胰岛素的2型糖尿病患者的获益且安全的选择。

要点

  • 成人2型糖尿病胰岛素治疗者使用Omnipod 5自动胰岛素输注系统13周后,HbA1c从基线8.2%降至7.4%,平均差-0.8(95%CI -1.0至-0.7)个百分点,非劣效和优效P均<.001。
  • 目标血糖范围(70-180 mg/dL)时间从45%增至66%,平均差20(95%CI 18至22)个百分点,P<.001。
  • 低血糖范围(<54 mg/dL和<70 mg/dL)时间百分比非劣于标准治疗;发生1例严重低血糖,无糖尿病酮症酸中毒或高渗性高血糖综合征。
  • HbA1c改善见于年龄、性别、种族和民族、保险等各亚组,无论是否使用GLP-1受体激动剂或SGLT-2抑制剂,也无论试验前餐时胰岛素方案如何。
  • 作者认为自动胰岛素输注可能是使用胰岛素的2型糖尿病患者的获益且安全的选择;该研究为非随机单臂试验。

适用人群与场景

  • 美国21个临床中心纳入的18至75岁2型糖尿病成人,筛查前使用胰岛素至少3个月。
  • 排除正在使用自动胰岛素输注系统的患者。
  • 研究场景为门诊临床试验,非急诊或ICU场景。

处置流程与药物剂量

  • 先进行14天标准治疗阶段,随后使用Omnipod 5自动胰岛素输注系统治疗13周。

研究设计与关键结果

  • 研究类型:单臂前瞻性试验,美国21个临床中心,305例参与者(平均[SD]年龄57[11]岁;175例[57%]女性;72例[24%]黑人,66例[22%]西班牙裔或拉丁裔,153例[50%]白人),289例(95%)完成试验。
  • 基线治疗:223例(73%)使用每日多次注射,63例(21%)使用基础胰岛素无餐时胰岛素,17例(6%)使用胰岛素泵,188例(62%)使用持续葡萄糖监测,168例(55%)使用GLP-1受体激动剂,134例(44%)使用SGLT-2抑制剂。
  • 主要终点:HbA1c从基线平均(SD)8.2%(1.3)降至13周7.4%(0.9),平均差-0.8(95%CI -1.0至-0.7)个百分点,非劣效和优效P均<.001。
  • 目标血糖范围(70-180 mg/dL)时间从平均(SD)45%(25)增至66%(17),平均差20(95%CI 18至22)个百分点,P<.001。
  • 低血糖范围<54 mg/dL和<70 mg/dL的时间百分比非劣于标准治疗。
  • 安全性:1例严重低血糖,无糖尿病酮症酸中毒或高渗性高血糖综合征。
  • 亚组:HbA1c改善见于年龄、性别、种族和民族、保险等各亚组,无论是否使用GLP-1受体激动剂或SGLT-2抑制剂,也无论试验前餐时胰岛素方案如何。

证据类型、等级与局限

  • 证据类型:单臂前瞻性非随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为自动胰岛素输注可能是使用胰岛素的2型糖尿病患者的获益且安全的选择。
  • 该研究为非随机单臂试验,未设平行对照组,结论需进一步研究验证。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: There is a need for additional treatment options for people with type 2 diabetes treated with insulin. Given the limited data on the use of automated insulin delivery (AID) systems in type 2 diabetes, studies evaluating their safety and efficacy are important.

OBJECTIVE: To evaluate the association of AID with hemoglobin A1c (HbA1c) levels in a diverse cohort of adults with type 2 diabetes.

DESIGN, SETTING, AND PARTICIPANTS: This single-arm prospective trial was conducted at 21 clinical centers in the United States among individuals aged 18 to 75 years with type 2 diabetes who had been using insulin for at least 3 months prior to screening. Participants with AID system use were excluded. The study started with a 14-day standard therapy phase, followed by 13 weeks of treatment with the investigational device. The first participant was enrolled April 11, 2023, and the last participant follow-up visit was February 29, 2024.

INTERVENTION: Participants used the Omnipod 5 AID System for 13 weeks following the 14-day standard therapy phase.

MAIN OUTCOMES AND MEASURES: Primary outcome was change in HbA1c level at 13 weeks, tested sequentially for noninferiority (0.3% margin) and superiority, compared with baseline.

RESULTS: Among 305 participants (mean [SD] age, 57 [11] years; 175 [57%] female; 72 [24%] Black, 66 [22%] Hispanic or Latino, and 153 [50%] White), 289 (95%) completed the trial. At baseline, 223 (73%) were using multiple daily injections, 63 (21%) were using basal insulin without bolus, 17 (6%) were using an insulin pump, 188 (62%) were using continuous glucose monitoring, 168 (55%) were using glucagon-like peptide-1 receptor agonists (GLP-1RAs), and 134 (44%) were using sodium-glucose transport protein 2 inhibitors (SGLT-2is). Following AID use, HbA1c levels decreased from a mean (SD) of 8.2% (1.3) at baseline to 7.4% (0.9) at 13 weeks (mean difference, -0.8 [95% CI, -1.0 to -0.7] percentage points; P < .001 for noninferiority and superiority). Improvement was seen across various subgroups (age, sex, race and ethnicity, insurance), and notably with or without use of GLP-1RAs or SGLT-2is and regardless of pretrial mealtime insulin regimen. Time in target glucose range (70-180 mg/dL) increased from a mean (SD) of 45% (25) to 66% (17) (mean difference, 20 [95% CI, 18 to 22] percentage points; P < .001). Percentage of time in hypoglycemic ranges of less than 54 mg/dL and less than 70 mg/dL was noninferior compared with standard therapy. There was 1 episode of severe hypoglycemia and none of diabetic ketoacidosis or hyperosmolar hyperglycemic syndrome.

CONCLUSIONS AND RELEVANCE: In this nonrandomized clinical trial, HbA1c levels were lower in a diverse cohort of adults with type 2 diabetes following AID initiation, suggesting that AID may be a beneficial and safe option for people with type 2 diabetes using insulin.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05815342.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Pasquel FJ, Davis GM, Huffman DM, et al. Automated Insulin Delivery in Adults With Type 2 Diabetes: A Nonrandomized Clinical Trial. JAMA Netw Open. 2025. PMID: 39951268. doi:10.1001/jamanetworkopen.2024.59348

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。